Albemarle Corporation

Sources: FY2024 and FY2025 from the 4Q25 release and 10-K FY2025 (FY2024 as revised). FY2021–FY2023 from the respective Forms 10-K as originally reported.

Income statement

Net sales CAGR FY2021–FY2025: 11.5%.

Notes on comparability:

• Adjusted EBITDA for FY2021 and FY2022 is on the definition in force at the time, which included Windfield equity income after tax. FY2023 onward uses the revised definition. The FY2023 figure is approximate (the release states USD 2.8 billion, or USD 3.4 billion before a USD 604 million inventory charge).

• Unadjusted EBITDA, as reconciled by the company, was USD 512.6 million in FY2025 and negative USD 338.1 million in FY2024. [4Q25 release]

• FY2025 adjusted diluted EPS was negative USD 0.79 (FY2024: negative USD 2.34). [4Q25 release]

Commentary.

Revenue: Sales tripled between FY2021 and FY2023 as lithium prices rose to about USD 80/kg and volumes grew. They then fell 44% in FY2024 as prices dropped by 85–95% from the January 2023 peak. FY2025 sales fell a further 4% despite volume growth in every segment. [10-K FY2025, Item 1A]

Gross profit: The FY2023 and FY2024 margins were hit by spodumene bought at high prices flowing through cost of goods sold as selling prices fell, including a USD 604 million lower-of-cost-or-market charge in Q4 2023. FY2025 gross margin recovered to 13.0% on cost savings and lower-cost inventory.

Operating income: FY2024 includes USD 1,134.3 million of restructuring charges and asset write-offs (Kemerton). FY2025 includes a USD 181.1 million goodwill impairment and a USD 245.6 million long-lived asset impairment, both on the Refining Solutions business. [4Q25 release]

Net income: FY2021 was depressed by the USD 665 million Huntsman settlement. FY2025 includes a full valuation allowance on US deferred tax assets recorded in Q4 and USD 88.1 million of discrete tax expense tied to the Ketjen entities. Preferred dividends of USD 166.8 million a year reduce income available to common shareholders. [4Q25 release]

Balance sheet

FY2025 current assets and liabilities include USD 371.8 million and USD 191.8 million, respectively, held for sale (Ketjen).

Position at 30 June 2026. Cash USD 1,631.7 million; total debt USD 1,876.8 million (USD 74.7 million current, USD 1,802.1 million long-term); total equity USD 10,533.9 million; total assets USD 15,905.1 million. Liquidity was about USD 3.2 billion, including an undrawn USD 1.5 billion revolver. Net debt to adjusted EBITDA as defined in the credit agreement was about 0.5x on trailing adjusted EBITDA of USD 2,016.3 million. [2Q26 release]

Commentary. Total debt peaked at about USD 4.2 billion in FY2023 to fund capex of USD 2.1 billion. The March 2024 preferred issue (USD 2.24 billion net) moved funding from debt to equity-like capital. The March 2026 tender and redemption cut debt by about USD 1.3 billion, funded by the Ketjen and Eurecat proceeds and cash on hand. Goodwill fell in FY2025 because of the Refining Solutions impairment and the reclassification to held for sale.

Cash flow

Commentary. FY2025 operating cash flow of USD 1.28 billion was 117% of adjusted EBITDA. It was helped by the USD 350 million customer prepayment, a USD 212 million inventory reduction and cost savings. Capex fell 65% to USD 590 million as expansion projects were stopped or completed. First-half 2026 operating cash flow was USD 1,056.2 million and capex USD 170.4 million, giving free cash flow of about USD 886 million. Q2 2026 benefited from a larger Talison dividend and non-recurring working capital gains. [4Q25 and 2Q26 releases]

Ratios

Definitions: ROE uses net income attributable to Albemarle over average Albemarle shareholders' equity. ROA uses the same numerator over average total assets. The ROIC proxy is operating income over year-end total debt plus total equity; it excludes equity income from Talison and so understates true returns in strong years. Net debt to adjusted EBITDA here uses reported balance-sheet debt; the credit-agreement ratio adds 49% of Windfield's debt and was about 2.0x at FY2025. The company's own adjusted ROIC measure is used for incentive pay but its values are not publicly disclosed on a comparable annual basis. The 2023–2025 performance share units tied to adjusted ROIC paid out at 0%. [Proxy 2026]

Recent quarters

Q3 2025 figures are derived by subtracting reported quarters from the full year and were not checked against the Q3 2025 release. Trailing twelve-month net sales to 30 June 2026 were about USD 5.91 billion.

Management guidance for FY2026. The company gives price-scenario "outlook considerations" in place of point guidance. [2Q26 release]

First-half 2026 adjusted EBITDA of USD 1.52 billion is consistent with the middle scenario. With Chinese carbonate at roughly USD 17.7–20/kg in late September, the second half is tracking at or slightly below that scenario's price assumption.

Consensus. Analysts expect a very large rise in FY2026 earnings from the FY2025 loss; one vendor cites growth of more than 1,500%. Estimates have been trimmed since July. Price targets average about USD 171, some 60% above the share price, which suggests that either targets or the share price will have to adjust.

Bull case.

1. Earnings power is proven at mid-cycle prices. At about USD 20/kg the company earned USD 858 million of adjusted EBITDA in a single quarter and converted 83% of it to cash. At USD 15.1 billion of enterprise value the shares trade at about 7.5x trailing adjusted EBITDA that still includes two trough quarters.

2. The cost base and balance sheet have been reset. USD 450 million of savings, capex down from USD 1.7 billion to about USD 0.5 billion, and leverage at 0.5x mean the company can now fund dividends and growth from internal cash even in a weak year.

3. Demand has a second engine. Stationary storage and data-centre power needs add to electric-vehicle growth, while Specialties is benefiting from firmer bromine prices and semiconductor demand.

Bear case.

1. Price is the only variable that matters, and it is weakening. The company's own table shows adjusted EBITDA of USD 0.9–1.0 billion at USD 10/kg. Chinese supply responds quickly to higher prices, and futures fell through September 2026.

2. Per-share value will be diluted and reported earnings are low quality. The preferred conversion adds roughly 15% to the share count. Trailing GAAP EPS is USD 0.27. Tax valuation allowances, equity-income accounting and recurring "unusual" items make earnings hard to read.

3. Structural and governance questions remain. Key resources are operated by partners, most active conversion is in China, about USD 1 billion was lost on Kemerton, and a CEO from outside the company and the chemicals industry takes over in February 2027.

Catalysts and monitorables for the next 12 months.

• Q3 2026 results on 4 November 2026: realised price against the USD 19.53/kg of Q2, sales volumes, and Talison dividends.

• Chinese lithium carbonate and spodumene prices after the October holiday period.

• FY2027 outlook framework in February 2027 and any restart decision for idled capacity.

• Arrival of Ragnar Udd on 1 February 2027 and any strategy or capital-allocation review.

• Conversion of the mandatory convertible preferred around March 2027.

• Credit rating outlook actions following the deleveraging.

• Greenbushes CGP3 ramp after the June fire; Wodgina output.

• Bromine price stability and the Middle East situation for JBC.

• Use of cash: debt, dividend growth, a first buyback since before 2021, or acquisitions.

• EU regulatory decisions on brominated flame retardants; US and Chinese trade policy.

Analyst verdict. Albemarle enters the final quarter of 2026 in better operating and financial condition than at any time since 2022, and with a share price that has halved in five months. Both facts are true because the company is a price-taker. Management has done what it can control. It cut USD 450 million of cost, reduced capital spending by two-thirds, sold control of a non-core catalysts business, retired USD 1.3 billion of debt and brought leverage to about half a turn. The result is a business that generated nearly USD 900 million of free cash flow in the first half of 2026 at a lithium price of roughly USD 20/kg, and that broke even on cash at USD 10/kg.

What it cannot control is whether USD 20/kg holds. The September decline in Chinese futures and the market's response show that investors treat the first-half recovery as cyclical. The company's own scenario table makes the sensitivity plain: each USD 10/kg is worth about USD 1.5–1.8 billion of adjusted EBITDA.

The resource quality is not in dispute. The discipline is recent and was learned expensively at Kemerton. The appointment of a BHP commercial executive as CEO suggests the board wants the company run as a low-cost resource producer through the cycle, and the reduced capex plan supports that reading.

Valuation at about 7.5x trailing adjusted EBITDA and 1.5x book is undemanding if prices hold near current levels and expensive if they return to 2025 levels. The balance sheet now gives shareholders time. The principal items to watch are the Q3 realised price, the 2027 framework, and what the incoming CEO chooses to do with a much stronger cash position. The dossier supports a constructive but price-contingent view.